Acute Stress Disorder vs. PTSD: Medication Timeline After an Accident

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 10 min read

Acute stress disorder (ASD) and post-traumatic stress disorder (PTSD) are distinct diagnoses separated by a critical timeline: ASD occurs within 3 days to 1 month after trauma, while PTSD is diagnosed after symptoms persist beyond 1 month. The pharmacotherapy approach differs meaningfully between these two conditions, and understanding the medication timeline is essential for both treatment and case documentation.

Acute stress disorder (ASD) and post-traumatic stress disorder (PTSD) are distinct clinical diagnoses separated by a critical timeline: ASD is diagnosed when trauma symptoms appear between 3 days and 1 month after the accident, while PTSD is diagnosed when symptoms persist or emerge beyond 1 month. The pharmacotherapy approach differs meaningfully between these conditions, and the medication timeline itself serves as powerful documentation of the psychological trajectory from acute trauma response to chronic psychiatric condition.

• ASD develops within 3 days to 1 month of the accident; PTSD is diagnosed after 1 month of persistent symptoms
• Approximately 50% of individuals with ASD go on to develop PTSD, making early treatment critical
• ASD pharmacotherapy focuses on short-term symptom management; PTSD requires sustained serotonergic treatment
• LienScripts covers all medications for both ASD and PTSD under a pharmacy lien at zero upfront cost
• The medication transition from ASD to PTSD treatment documents the progression of psychological injury

Distinguishing ASD from PTSD

Acute Stress Disorder

ASD shares many symptoms with PTSD -- intrusive memories, avoidance behavior, negative mood changes, hyperarousal -- but is characterized by prominent dissociative symptoms (feeling detached from reality, emotional numbness, inability to recall aspects of the accident). The diagnosis requires symptoms persisting at least 3 days but no more than 1 month.

Post-Traumatic Stress Disorder

PTSD is diagnosed when trauma symptoms persist beyond 1 month. The symptom clusters include re-experiencing (flashbacks, nightmares), avoidance (steering clear of reminders), negative cognition and mood changes, and hyperarousal (hypervigilance, exaggerated startle response, sleep disruption). PTSD is a chronic condition that frequently requires 12-24 months or more of pharmacotherapy.

The Diagnostic Transition

The transition from ASD to PTSD is a clinically significant event documented by the medication record. When short-term anxiolytics prescribed for ASD are replaced or augmented by long-term SSRIs for PTSD, the pharmacy record captures this diagnostic progression.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist with clinical experience in psychiatric pharmacy, explains: "The medication timeline tells the story of the psychological injury's evolution. A patient who starts on hydroxyzine for acute anxiety and transitions to sertraline for PTSD, then adds prazosin for nightmares -- each prescription change documents a clinical determination that the condition is worsening or not resolving, which directly supports the non-economic damage narrative."

Pharmacotherapy for Acute Stress Disorder

Short-Term Anxiolytics

Hydroxyzine 25-50 mg as needed provides non-addictive anxiolysis during the acute phase. It addresses the immediate anxiety, agitation, and sleep disruption without the dependence concerns of benzodiazepines.

Short-Term Benzodiazepines (Limited Use)

Benzodiazepines (lorazepam 0.5-1 mg, clonazepam 0.25-0.5 mg) may be prescribed for severe acute stress symptoms. However, emerging evidence suggests that benzodiazepine use immediately after trauma may interfere with fear extinction learning and potentially increase PTSD risk. Many clinicians now limit or avoid benzodiazepines in the acute phase.

Early SSRI Initiation

Some clinicians initiate SSRI therapy during the ASD phase, particularly when clinical indicators suggest high PTSD risk. Early sertraline or escitalopram initiation may reduce the probability of ASD progressing to PTSD. The decision to start long-term medication during the ASD phase documents the clinician's assessment that the patient is at high risk for chronic PTSD.

Beta-Blockers

Propranolol administered in the acute phase may attenuate the consolidation of traumatic memories by blocking noradrenergic signaling during the critical post-trauma window. While research results are mixed, its use in ASD documents a proactive treatment approach.

Pharmacotherapy for PTSD

First-Line: SSRIs

Sertraline (50-200 mg) and paroxetine (20-60 mg) are the only two FDA-approved medications for PTSD. Escitalopram and fluoxetine are used off-label with strong evidence. SSRI therapy for PTSD requires a minimum of 12 months, with many patients requiring 2+ years of continuous treatment.

Second-Line: SNRIs

Venlafaxine (75-225 mg) is recommended when SSRIs provide insufficient PTSD symptom control. The transition from SSRI to SNRI in pharmacy records documents treatment resistance and greater PTSD severity.

Adjunctive Prazosin

Prazosin (1-15 mg at bedtime) specifically targets PTSD-related nightmares through alpha-1 adrenergic blockade. Its addition to an SSRI regimen documents the presence of trauma nightmares as a distinct symptom cluster.

Adjunctive Agents

Trazodone for PTSD-related insomnia, buspirone for residual anxiety, and propranolol for hyperarousal symptoms may be added as the PTSD treatment plan evolves. Each addition documents a symptom not adequately controlled by the primary agent.

The Medication Timeline as Evidence

The progression from ASD to PTSD pharmacotherapy creates a documentary arc:

1. Week 1-4: Hydroxyzine or short-term anxiolytic documents acute distress
2. Month 1-2: SSRI initiation documents diagnosis of persistent anxiety/PTSD
3. Month 2-4: SSRI dose escalation documents inadequate initial response
4. Month 3-6: Addition of prazosin or second agent documents treatment complexity
5. Month 6+: Continued refills document chronicity

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that captures this entire medication timeline.

Pharmacy Lien Coverage

LienScripts covers all ASD and PTSD medications -- from acute-phase anxiolytics through long-term SSRIs, prazosin, and adjunctive agents -- under a pharmacy lien at zero upfront cost throughout the case.

Related Resources

• PTSD Medication Management in Personal Injury
• Sertraline vs. Paroxetine for PTSD
• PTSD Nightmares: Medication Management After an Accident